Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dose-finding study of MR-130A-01 contraceptive NGMN patch
2022-003219-26Phase 2Completed
- Sponsor
- Mylan
- Start
- Nov 2022
- Modality
- Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of MR-130A-01 (3 arms), sponsored by Mylan. Primary endpoint: Proportion of responders (overall ovulation inhibition). Started Nov 2022; status: completed.
02
Drugs
MR-130A-01
Beyond the preview
Go deeper on 2022-003219-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003219-26.